| Name | Title | Contact Details |
|---|
Versicolor Technologies has developed the world`s first cosmetic and therapeutic technology platform to address pigmentation and skin aging, by leveraging small molecule compounds produced naturally in the human microbiome.
ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.
Inflo Health is a company that helps imaging centers and hospitals realize more revenue and provide the best patient outcomes.
Pancreatic Cancer Canada is a national foundation dedicated to improving pancreatic cancer survival rates through research, awareness, education, and advocacy in Canada.
Sonic Innovations, Inc. is a hearing aid company focused on the therapeutic aspects of hearing care. The Company designs, develops, manufactures and markets digital hearing aids. It has developed digital signal processing (DSP) technologies based on an